α and 1–β [Power / Sample Size]

posted by Helmut Homepage – Vienna, Austria, 2017-12-27 12:57  – Posting: # 18099
Views: 22,444

Hi Yura,

» If at GMR=0.95 and CV=0.25 calculation has to be carried out at N = 28-30 subjects, and you carry out on 50 subjects, there can be questions on forced bioequivalence :cool:

If I got your example correctly, 28–30 subjects mean 81–83% power. In some guidelines 80–90% power are recommended. 90% power would require 38 subjects. 50 subjects would mean 96% power (BE-proff’s “big wallet”).
However, such a sample size should concern only the IEC (assessing the risk for the study participants). If the protocol was approved by the IEC and the competent regulatory agency, performed as planned and by chance show an even higher “power”, an eyebrow of the assessor might be raised but technically (Type I Error is controlled) there is no reason to question the study.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,871 posts in 4,212 threads, 1,364 registered users;
online 8 (0 registered, 8 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 12:41 CEST

A drug is not bad. A drug is a chemical compound.
The problem comes in when people who take drugs treat them
like a license to behave like an asshole.    Frank Zappa

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5